+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Opisthorchiasis Treatment - Global Strategic Business Report

  • PDF Icon

    Report

  • 476 Pages
  • July 2025
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 6105941
The global market for Opisthorchiasis Treatment was estimated at US$389.5 Million in 2024 and is projected to reach US$504.6 Million by 2030, growing at a CAGR of 4.4% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Opisthorchiasis Treatment market.

Global Opisthorchiasis Treatment Landscape - Key Trends & Drivers Summarized

Why Is Opisthorchiasis a Public Health Concern and What Triggers the Need for Treatment?

Opisthorchiasis is a parasitic infection caused by liver flukes, primarily Opisthorchis viverrini and Opisthorchis felineus, acquired through consumption of raw or undercooked freshwater fish. The disease is endemic in regions of Southeast Asia, Eastern Europe, and parts of Siberia. Chronic infections can persist for decades, damaging the liver, gallbladder, and bile ducts. Over time, they can lead to severe complications such as cholangitis, cholecystitis, and a heightened risk of cholangiocarcinoma.

Widespread consumption of traditional raw fish dishes in endemic areas sustains transmission. Infected individuals may remain asymptomatic for years, contributing to underdiagnosis and delayed treatment. Once symptoms emerge, they may include abdominal pain, fatigue, indigestion, and hepatobiliary abnormalities. Increasing awareness of liver fluke-related complications and broader surveillance programs are prompting healthcare providers to pursue early intervention strategies. Accurate diagnosis, typically based on stool microscopy or advanced antigen detection methods, is critical for timely treatment.

What Therapies Are Available and How Effective Are They in Clinical Practice?

The primary pharmacological treatment for opisthorchiasis is praziquantel, a broad-spectrum antiparasitic agent administered in short-course regimens. It acts by disrupting calcium ion balance in the parasites, causing paralysis and death. Treatment is generally effective, with high cure rates and good tolerability. In some settings, albendazole is considered as an alternative, though it is typically less effective against Opisthorchis species. Repeat treatment may be required in cases of high parasite burden or reinfection.

Symptomatic management may be necessary in advanced cases involving biliary tract inflammation or fibrosis. Supportive therapies may include antispasmodics, hepatoprotective agents, and bile flow regulators. Surgical interventions may be required in cases involving complications such as gallstones or bile duct obstruction. Long-term follow-up is recommended for patients with repeated infections due to elevated risk of hepatobiliary cancers. Integration of antiparasitic treatment with public health interventions, such as mass drug administration campaigns, has been shown to reduce infection prevalence in endemic communities.

What Preventive and Systemic Measures Are Shaping Treatment Strategies?

Efforts to control opisthorchiasis are increasingly combining therapeutic intervention with public health education and food safety campaigns. Promotion of safe food preparation practices, especially discouraging consumption of raw or fermented freshwater fish, plays a critical role in reducing transmission. Community-wide deworming programs have been implemented in several endemic countries, supported by school-based screening and national control strategies.

Improvements in water sanitation, health education, and access to diagnostics are reinforcing treatment effectiveness. Research is ongoing into potential vaccines and more selective anthelmintic agents with improved safety profiles, especially for children and vulnerable populations. Enhanced surveillance systems, supported by digital tools and geospatial mapping, are enabling targeted intervention and outbreak containment. Partnerships between health ministries and international health organizations are contributing to long-term disease control objectives.

What Factors Are Driving Growth in the Opisthorchiasis Treatment Market?

Growth in the opisthorchiasis treatment market is driven by several factors. Persistent endemicity in parts of Asia and Eastern Europe is maintaining demand for diagnostic and therapeutic services. Increasing incidence of hepatobiliary diseases linked to chronic infection is prompting earlier medical intervention. Availability of effective, affordable anthelmintic drugs such as praziquantel is facilitating mass treatment initiatives. Expansion of public health infrastructure and disease monitoring programs is enabling broader access to care in rural and underserved areas. Rising awareness of foodborne parasitic risks and integration of treatment into national disease control frameworks are supporting consistent demand. These factors are collectively reinforcing the importance of timely, accessible, and community-level treatment strategies in managing opisthorchiasis globally.

Scope Of Study:

The report analyzes the Opisthorchiasis Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments: Type (Medications Type, Surgery Type); Diagnostic Procedure (Cholangiography Diagnostic Procedure, MRI Diagnostic Procedure, Ultrasonography Diagnostic Procedure, CT scan Diagnostic Procedure, Other Diagnostic Procedures); Symptom (Jaundice Symptom, Diarrhea Symptom, Fever Symptom, Splenomegaly Symptom, Weight loss Symptom, Tachycardia Symptom, Other Symptoms); End-Use (Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Medications Type segment, which is expected to reach US$323.2 Million by 2030 with a CAGR of a 3.6%. The Surgery Type segment is also set to grow at 6.0% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $106.1 Million in 2024, and China, forecasted to grow at an impressive 6.9% CAGR to reach $97.6 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Opisthorchiasis Treatment Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Opisthorchiasis Treatment Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Opisthorchiasis Treatment Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as AbbVie, Astellas Pharma, Bayer AG, Boehringer Ingelheim, Cipla Inc. and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 32 companies featured in this Opisthorchiasis Treatment market report include:

  • AbbVie
  • Astellas Pharma
  • Bayer AG
  • Boehringer Ingelheim
  • Cipla Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche
  • Gilead Sciences
  • GlaxoSmithKline plc
  • Hubei Zhongjia-Chem Pharmaceutical
  • Johnson & Johnson
  • Merck KGaA
  • Merck Sharp & Dohme (MSD)
  • Mankind Pharma
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Shin Poong Pharmaceutical Co., Ltd.
  • Sun Pharmaceutical Industries
  • Teva Pharmaceutical Industries Ltd.

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

  • Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
  • Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
  • Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
  • Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
  • Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
  • Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
  • Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Opisthorchiasis Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Foodborne Parasitic Infections in Southeast Asia Drives Demand for Opisthorchiasis Treatment Protocols
  • Expansion of Public Health Surveillance Programs Strengthens Early Detection and Community-Based Case Management
  • Increased Availability and Distribution of Antiparasitic Drugs Like Praziquantel Support Scalable Treatment Coverage
  • Growth in Awareness Campaigns on Raw Fish Consumption Risks Spurs Preventive Screening and Early Therapeutic Intervention
  • Integration of Diagnosis and Treatment Through Primary Care Networks Enhances Reach in Endemic Rural Areas
  • Support from Global Health Organizations for Helminthic Disease Control Accelerates Drug Access and Treatment Infrastructure
  • Advancements in Molecular Diagnostics and ELISA-Based Tests Improve Detection of Low-Intensity and Asymptomatic Infections
  • Development of Drug Resistance Monitoring Systems Strengthens Sustainability of Current First-Line Therapies
  • Expansion of School-Based Deworming Programs Includes Opportunistic Screening for Liver Fluke Infections
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Opisthorchiasis Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Opisthorchiasis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Opisthorchiasis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Opisthorchiasis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Medications Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Medications Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Medications Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Surgery Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Surgery Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Surgery Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Fever Symptom by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Fever Symptom by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Fever Symptom by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Splenomegaly Symptom by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Splenomegaly Symptom by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Splenomegaly Symptom by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Weight loss Symptom by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Weight loss Symptom by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Weight loss Symptom by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Tachycardia Symptom by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Tachycardia Symptom by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Tachycardia Symptom by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other Symptoms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other Symptoms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Other Symptoms by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Jaundice Symptom by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Jaundice Symptom by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Jaundice Symptom by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Diarrhea Symptom by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Diarrhea Symptom by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Diarrhea Symptom by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 40: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Cholangiography Diagnostic Procedure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Cholangiography Diagnostic Procedure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 43: World 16-Year Perspective for Cholangiography Diagnostic Procedure by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for MRI Diagnostic Procedure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for MRI Diagnostic Procedure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 46: World 16-Year Perspective for MRI Diagnostic Procedure by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Ultrasonography Diagnostic Procedure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Ultrasonography Diagnostic Procedure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 49: World 16-Year Perspective for Ultrasonography Diagnostic Procedure by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 50: World Recent Past, Current & Future Analysis for CT scan Diagnostic Procedure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 51: World Historic Review for CT scan Diagnostic Procedure by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 52: World 16-Year Perspective for CT scan Diagnostic Procedure by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 53: World Recent Past, Current & Future Analysis for Other Diagnostic Procedures by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 54: World Historic Review for Other Diagnostic Procedures by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 55: World 16-Year Perspective for Other Diagnostic Procedures by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Opisthorchiasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
CANADA
JAPAN
  • Opisthorchiasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
CHINA
  • Opisthorchiasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
EUROPE
  • Opisthorchiasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
FRANCE
  • Opisthorchiasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
GERMANY
  • Opisthorchiasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
ITALY
UNITED KINGDOM
  • Opisthorchiasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
SPAINRUSSIAREST OF EUROPE
ASIA-PACIFIC
  • Opisthorchiasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
AUSTRALIA
  • Opisthorchiasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
INDIA
  • Opisthorchiasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Opisthorchiasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Opisthorchiasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Opisthorchiasis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AbbVie
  • Astellas Pharma
  • Bayer AG
  • Boehringer Ingelheim
  • Cipla Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche
  • Gilead Sciences
  • GlaxoSmithKline plc
  • Hubei Zhongjia-Chem Pharmaceutical
  • Johnson & Johnson
  • Merck KGaA
  • Merck Sharp & Dohme (MSD)
  • Mankind Pharma
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Shin Poong Pharmaceutical Co., Ltd.
  • Sun Pharmaceutical Industries
  • Teva Pharmaceutical Industries Ltd.

Table Information